A real-world study on efficacy, safety and economy of Ceftazidime-Avibactam versus polymyxin B in the treatment of infections due to carbapenem-resistant enterobacteriaceae

A real-world study on efficacy, safety and economy of ceftazidime-avibactam versus polymyxin B in the treatment of infections due to carbapenem-resistant enterobacteriaceae

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300067946

Enrollment

Unknown

Registered

2023-02-01

Start date

2023-02-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carbapenem-resistant enterobacteriaceae infection

Interventions

Ceftazidime-Avibactam therapy:None

polymyxin B therapy:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Inpatients discharged between 2020.7.1-2024.6.30; 2. Prescribed ceftazidime-avibactam or polymyxin B for antibiotics treatment.

Exclusion criteria

Exclusion criteria: 1. Without a diagnosis or infection basis of carbapenem-resistant enterobacteriaceae infection during hospitalization; 2. Patients with a course of ceftazidime-avibactam or polymyxin B less than 72h; 3. Combined use of ceftazidime-avibactam and polymyxin B in antibiotics treatment; 4. Patients with gram-negative bacilli as colonizing or polluting bacteria.

Design outcomes

Primary

Measure	Time frame
28-day all-cause mortality;clinical cure rate;	—

Secondary

Measure	Time frame
Microbiological clearance rate;vital signs;Treatment-related adverse reactions;outcome of patients;Blood routine examination;biochemical indexes;C-Reactive protein;procalcitonin;cost;	—

Countries

China

Contacts

Public ContactZhang Haixia

Nanjing Drum Tower Hospital

zhx_510@hotmail.com+86 25 83106666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 30, 2026